BURACCHI CHIARA

Bugarin, C., Antolini, L., Buracchi, C., Matarraz, S., Coliva, T., Van der Velden, V., et al. (2024). Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of Juvenile Myelomonocytic Leukemia. HAEMATOLOGICA, 109(2 (February, 2024)), 521-532 [10.3324/haematol.2023.282805]. Detail

Buracchi, C., Belotti, D., Moretti, A., Calabretta, L., Risca, G., Capelli, C., et al. (2023). Deep immunophenotypic characterization of CARCIK-CD19 pre-infusion cellular product by advanced multiparametric flow cytometry. Intervento presentato a: ESLHO Symposium, Salamanca, Spain. Detail

Verbeek, M., Rodríguez, B., Sedek, L., Laqua, A., Buracchi, C., Buysse, M., et al. (2023). Minimal residual disease assessment in B-cell precursor acute lymphoblastic leukemia by semi-automated identification of normal hematopoietic cells: A EuroFlow study. CYTOMETRY. PART B, CLINICAL CYTOMETRY [10.1002/cyto.b.22143]. Detail

Guarini, A., Radice, G., Peragine, N., Buracchi, C., De Propris, M., Di Rocco, A., et al. (2023). Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia. CANCERS, 15(9) [10.3390/cancers15092411]. Detail

Verbeek, M., Buracchi, C., Laqua, A., Nierkens, S., Sedek, L., Flores-Montero, J., et al. (2022). Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study. BRITISH JOURNAL OF HAEMATOLOGY, 197(1 (April 2022)), 76-81 [10.1111/bjh.17992]. Detail